Abstract
Morbidity and mortality from opioid use disorders (OUD) and other substance use disorders (SUD) is a major public health crisis, yet there are few medications to treat them. There is an urgency to accelerate SUD medication development. We present an integrated drug repurposing strategy that combines computational prediction, clinical corroboration using electronic health records (EHRs) of over 72.9 million patients and mechanisms of action analysis. Among top-ranked repurposed candidate drugs, tramadol, olanzapine, mirtazapine, bupropion, and atomoxetine were associated with increased odds of OUD remission (adjusted odds ratio: 1.51 [1.38–1.66], 1.90 [1.66–2.18], 1.38 [1.31–1.46], 1.37 [1.29–1.46], 1.48 [1.25–1.76], p value < 0.001, respectively). Genetic and functional analyses showed these five candidate drugs directly target multiple OUD-associated genes including BDNF, CYP2D6, OPRD1, OPRK1, OPRM1, HTR1B, POMC, SLC6A4 and OUD-associated pathways, including opioid signaling, G-protein activation, serotonin receptors, and GPCR signaling. In summary, we developed an integrated drug repurposing approach and identified five repurposed candidate drugs that might be of value for treating OUD patients, including those suffering from comorbid conditions.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Volkow ND, McLellan AT. Opioid abuse in chronic pain-misconceptions and mitigation strategies. N. Engl J Med. 2016;374:1253–63. https://doi.org/10.1056/NEJMra1507771.
Volkow ND, Koob GF, McLellan AT. Neurobiologic advances from the brain disease model of addiction. N. Engl J Med. 2016;374:363–371.
Volkow ND, Morales M. The brain on drugs: from reward to addiction. Cell. 2015;162:712–725.
National Survey on Drug Use and Health—SAMHSA. Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health. National Survey on Drug Use and Health. 2018. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396:1204–22. https://doi.org/10.1016/S0140-6736(20)30925-9.
Department of Health and Human Services. HHS acting secretary declares public health emergency to address national opioid crisis. Department of Health and Human Services; 2017. p. 2016–7. https://www.hhs.gov/about/news/2017/10/26/hhs-acting-secretary-declares-public-health-emergency-address-national-opioid-crisis.html.
Centers for Disease Control and Prevention (CDC) National Center for Health Statistics. Mortality. Centers for Disease Control and Prevention. 2020. https://www.cdc.gov/nchs/data/health_policy/Provisional-Drug-Overdose-Deaths-by-Quarter-Demographic-Characteristics-Q1-2020.pdf.
Volkow ND, Skolnick P. New medications for substance use disorders: challenges and opportunities. Neuropsychopharmacology. 2012;37:290–292.
Mullard A. New drugs cost US $2.6 billion to develop. Nat Rev Drug Discov. 2014;13:877. https://doi.org/10.1038/nrd4507.
National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Health Sciences Policy; Forum on Neuroscience and Nervous System Disorders. Advancing Therapeutic Development for Pain and Opioid Use Disorders Through Public-Private Partnerships: Proceedings of a Workshop. Washington (DC): National Academies Press (US); 2018.
Ashburn TT, Thor KB. Drug repurposing: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3:673–683.
Srivastava AB, Mariani JJ, Levin FR. New directions in the treatment of opioid withdrawal. Lancet. 2020;395:1938–48. https://doi.org/10.1016/S0140-6736(20)30852-7.
Li J, Zheng S, Chen B, Butte AJ, Swamidass SJ, Lu Z. A survey of current trends in computational drug repurposing. Brief Bioinform. 2016;17:2–12.
Wang Q, Xu R. Disease comorbidity-guided drug repurposing: a case study in schizophrenia. AMIA Annu Symp Proc. 2018;2018:1300–9.
Nagaraj AB, Wang Q, Joseph P, Zheng CL, Chen Y, Kovalenko O, et al. Using a novel computational drug repurposing approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene. 2017. https://doi.org/10.1038/onc.2017.328.
Chen Y, Xu R. Context-sensitive network-based disease genetics prediction and its implications in drug discovery. Bioinformatics 2017;33:1031–9. https://doi.org/10.1093/bioinformatics/btw737.
Xu R, Wang Q. A genomics-based systems approach towards drug repurposing for rheumatoid arthritis. BMC Genom. 2016;17:518 https://doi.org/10.1186/s12864-016-2910-0.
Xu R, Wang Q. PhenoPredict: a disease phenome-wide drug repurposing approach towards schizophrenia drug discovery. J Biomed Inf. 2015;56:348–55. https://doi.org/10.1016/j.jbi.2015.06.027.
Chen Y, Xu R. Context-sensitive network-based disease genetics prediction and its implications in drug discovery. Bioinformatics. 2017;33:1031–9. https://doi.org/10.1093/bioinformatics/btw737.
Chen Y, Xu R. Context-sensitive network analysis identifies food metabolites associated with Alzheimer’s disease: an exploratory study. BMC Med Genom. 2019;12:17 https://doi.org/10.1186/s12920-018-0459-2.
Zheng C, Xu R. Large-scale mining disease comorbidity relationships from post-market drug adverse events surveillance data. BMC Bioinforma. 2018;19:500.
Zhou M, Chen Y, Xu R. A drug-side effect context-sensitive network approach for drug target prediction. Bioinformatics. 2019;35:2100–7. https://doi.org/10.1093/bioinformatics/bty906.
Zhou M, Zheng C, Xu R. Combining phenome-driven drug-target interaction prediction with patients’ electronic health records-based clinical corroboration toward drug discovery. Bioinformatics. 2020;36:i436–i444. https://doi.org/10.1093/bioinformatics/btaa451.
Kuhn M, Letunic I, Jensen LJ, Bork P. The SIDER database of drugs and side effects. Nucleic Acids Res. 2016;44:D1075–9. https://doi.org/10.1093/nar/gkv1075.
Franceschini A, Szklarczyk D, Frankild S, Kuhn M, Simonovic M, Roth A, et al. STRING v9.1: protein-protein interaction networks, with increased coverage and integration. Nucleic Acids Res. 2013;41:808–15. https://doi.org/10.1093/nar/gks1094.
Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018;46:D1074–82. https://doi.org/10.1093/nar/gkx1037.
Xu R, Wang Q, Li L. A genome-wide systems analysis reveals strong link between colorectal cancer and trimethylamine N-oxide (TMAO), a gut microbial metabolite of dietary meat and fat. BMC Genom. 2015;16:S4 https://doi.org/10.1186/1471-2164-16-S7-S4.
Xu R, Wang Q. Towards understanding brain-gut-microbiome connections in Alzheimer’s disease. BMC Syst Biol 2016;10:63 https://doi.org/10.1186/s12918-016-0307-y.
Wang Q, Xu R. CoMNRank: an integrated approach to extract and prioritize human microbial metabolites from MEDLINE records [published online ahead of print, 2020 Aug 11]. J Biomed Inf. 2020;109:103524 https://doi.org/10.1016/j.jbi.2020.103524.
IBM Explorys. IBM Watson Health. IBM Explorys. https://www.ibm.com/watson/health/explorys/. Accessed June–August 2020. Accessed June–Aug 2020.
Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004;32:D267–D270. https://doi.org/10.1093/nar/gkh061.
SNOMED International. The systematized nomenclature of medicine—Clinical Terms (SNOMED CT). SNOMED International. 2020. http://www.snomed.org/snomed-ct/why-snomed-ct.
Zhou M, Xu R, Kaelber DC, Gurney ME. Tumor necrosis factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis. PLoS ONE. 2020;15:e0229819. https://doi.org/10.1371/journal.pone.0229819.
Wang QQ, Kaelber DC, Xu R, Volkow ND. COVID-19 risk and outcomes in patients with substance use disorders: analyses from electronic health records in the United States. Mol Psychiatry. 2020:1–10. https://doi.org/10.1038/s41380-020-00880-7.
Wang QQ, Xu R, Volkow ND. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. World Psychiatry. 2020. https://doi.org/10.1002/wps.20806.
Wang QQ, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes of cancers and coronavirus disease 2019 from electronic health 4 records in the US. JAMA Oncol. 2020. https://doi.org/10.1001/jamaoncol.2020.6178.
Wang QQ, Berger NA, Xu R. When hematologic malignancies meet COVID-19 in the United States: infections, death and disparities. Blood Rev. https://doi.org/10.1016/j.blre.2020.100775.
The National Library of Medicine (NLM). DailyMed. The National Library of Medicine. https://healthdata.gov/dataset/dailymed. Accessed June–Aug 2020.
Kuritz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: applications and recent developments. Annu Rev Public Health. 1988;9:123–160. https://doi.org/10.1146/annurev.pu.09.050188.001011.
Wang SC, Chen YC, Lee CH, Cheng CM. Opioid addiction, genetic susceptibility, and medical treatments: a review. Int J Mol Sci 2019;20:4294 https://doi.org/10.3390/ijms20174294.
Darcq E, Kieffer BL. Opioid receptors: drivers to addiction? Nat Rev Neurosci. 2018;19:499–514. https://doi.org/10.1038/s41583-018-0028-x.
Crist RC, Reiner BC, Berrettini WH. A review of opioid addiction genetics. Curr Opin Psychol. 2019;27:31–35.
Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M. STITCH 5: augmenting protein-chemical interaction networks with tissue and affinity data. Nucleic Acids Res. 2016;44:D380–D384. https://doi.org/10.1093/nar/gkv1277.
Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 2011;27:1739–40. https://doi.org/10.1093/bioinformatics/btr260.
Wang Q, Xu R. Data-driven multiple-level analysis of gut-microbiome-immune-joint interactions in rheumatoid arthritis. BMC Genom. 2019;20:124 https://doi.org/10.1186/s12864-019-5510-y.
Wang Q, Li L, Xu R. A systems biology approach to predict and characterize human gut microbial metabolites in colorectal cancer. Sci Rep. 2018;8:6225 https://doi.org/10.1038/s41598-018-24315-0.
National Institute on Drug Abuse. Common comorbidities with substance use disorders research report. National Institute on Drug Abuse. 2018. https://www.drugabuse.gov/publications/drugfacts/comorbidity-substance-use-disorders-other-mental-illnesses.
Kaye AD. Tramadol, pharmacology, side effects, and serotonin syndrome: a review. Pain Physician. 2015;18:395–400.
Lofwall MR, Babalonis S, Nuzzo PA, Siegel A, Campbell C, Walsh SL. Efficacy of extended-release tramadol for treatment of prescription opioid withdrawal: a two-phase randomized controlled trial. Drug Alcohol Depend. 2013;133:188–97.
Sarkar S, Varshney M, Patil V, Lal R. Maintainence treatment of opioid dependence with tramadol. J Neurosci Rural Pr. 2017;8:S98.
Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, et al. In vitro and in vive biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry. 1997;58:28–36.
Al-Hasani R, Bruchas MR. Molecular mechanisms of opioid receptor-dependent signaling and behavior. Anesthesiology. 2011;115:1363–81. https://doi.org/10.1097/ALN.0b013e318238bba6.
Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3:760–773.
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.
Radcliff JA, Vellanki SC, Moore PS, Weisensell BJ, Cather JK. A retrospective chart review of outcomes resulting from a three-day tramadol taper for acute opioid withdrawal. J Addict Dis. 2018;37:252–8.
Stahl SM, Pradko JF, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A review of the neuropharmacology of bupropion, a dual norepinephrine and dopamine reuptake inhibitor. Prim Care Companion J Clin Psychiatry. 2004;6:159–66. https://doi.org/10.4088/pcc.v06n0403.
Hamdy MM, Elbadr MM, Barakat A. Bupropion attenuates morphine tolerance and dependence: Possible role of glutamate, norepinephrine, inflammation, and oxidative stress. Pharm Rep. 2018;70:955–62. https://doi.org/10.1016/j.pharep.2018.04.003.
Brackins T, Brahm NC, Kissack JC. Treatments for methamphetamine abuse: a literature review for the clinician. J Pharm Pr. 2011;24:541–50. https://doi.org/10.1177/0897190011426557.
Wong DT, Threlkeld PG, Best KL, Bymaster FP. A new inhibitor of norepinephrine uptake devoid of affinity for receptors in rat brain. J Pharm Exp Ther. 1982;222:61–5.
Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paed Drugs. 2009;11:203–26.
Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH. Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005;66:1234–8.
Lofwall MR, Walsh SL, Bigelow GE, Strain EC. Modest opioid withdrawal suppression efficacy of oral tramadol in humans. Psychopharmacology. 2007;194:381–393.
Cowie MR, Blomster JI, Curtis LH, Duclaux S, Ford I, et al. Electronic health records to facilitate clinical research. Clin Res Cardiol. 2017;106:1–9. https://doi.org/10.1007/s00392-016-1025-6.
Coorevits P, Sundgren M, Klein GO, Bahr A, Claerhout B, Daniel C, et al. Electronic health records: new opportunities for clinical research. J Intern Med. 2013;274:547–560. https://doi.org/10.1111/joim.12119.
Ahmad FS, Chan C, Rosenman MB, Post WS, Fort DG, Greenland P, et al. Validity of cardiovascular data from electronic sources: the Multi-Ethnic Study of Atherosclerosis and HealthLNK. Circulation. 2017;136:1207–1216. https://doi.org/10.1161/CIRCULATIONAHA.117.027436.
Safran C, Bloomrosen M, Hammond WE, Labkoff S, Markel-Fox S, Tang PC, et al. Toward a national framework for the secondary use of health data: an American Medical Informatics Association White Paper. J Am Med Inf Assoc. 2007;14:1–9. https://doi.org/10.1197/jamia.M2273.
Madden JM, Lakoma MD, Rusinak D, Lu CY, Soumerai SB. Missing clinical and behavioral health data in a large electronic health record (EHR) system. J Am Med Inform Assoc. 2016; https://doi.org/10.1093/jamia/ocw021.
The Substance Abuse and Mental Health Services Administration (SAMHSA). Key substance use and mental health indicators in the United States: results from the 2018 National Survey on Drug Use and Health. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/sites/default/files/cbhsq-reports/NSDUHNationalFindingsReport2018/NSDUHNationalFindingsReport2018.pdf. Accessed 12 Nov 2020.
Acknowledgements
We acknowledge support from Eunice Kennedy Shriver National Institute of Child Health & Human Development of the National Institutes of Health under the NIH Director’s New Innovator Award number DP2HD084068, NIH National Institute on Aging R01 AG057557, R01 AG061388, R56 AG062272, National Institute on Drug Addiction UG1DA049435, American Cancer Society Research Scholar Grant RSG-16-049-01—MPC, and The Clinical and Translational Science Collaborative (CTSC) of Cleveland 1UL1TR002548-01.
Author information
Authors and Affiliations
Contributions
RX conceived, designed, and supervised the study. MZ performed drug prediction and clinical evaluation. QW performed the mechanism of action study. RX, QW, MZ, and NDV drafted the manuscript. NDV, CLZ, and AR critically contributed to data interpretation and result discussion. All authors approved the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Rights and permissions
About this article
Cite this article
Zhou, M., Wang, Q., Zheng, C. et al. Drug repurposing for opioid use disorders: integration of computational prediction, clinical corroboration, and mechanism of action analyses. Mol Psychiatry 26, 5286–5296 (2021). https://doi.org/10.1038/s41380-020-01011-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41380-020-01011-y
This article is cited by
-
Mining comorbidities of opioid use disorder from FDA adverse event reporting system and patient electronic health records
BMC Medical Informatics and Decision Making (2022)
-
Computational drug repurposing based on electronic health records: a scoping review
npj Digital Medicine (2022)